Organon & Co

OGN

Market cap $3.51B

Bala Cynwyd, Pennsylvania--(Newsfile Corp. - June 2, 2026) - Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Organon & Co. ("Organon" or the "Company") (NYSE - OGN) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the sale of the Company to Sun Pharmaceutical Industries Limited for $14.00 per share in an all-cash transaction with an enterprise valuation of $11.75 billion. The investigation concerns whether the Organon Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the proposed transaction is paying fair value to shareholders of the Company.

Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Shin Hae-gon (right), Head of Overseas Sales at Hanmi Pharmaceutical, and Andreas Daugaard Jørgensen (left), Managing Director, Organon Asia Pacific Cluster, met at Organon's Malaysia office to discuss the expansion of Hanmi's combination therapies into the Southeast Asian market. SEOUL, South Korea, May 21, 2026 (GLOBE NEWSWIRE) -- Hanmi Pharmaceutical announced that it has signed a supply agreement with global healthcare company Organon to export three combination medicines for the Malaysian and Philippine markets, expanding the companies' partnership in Southeast Asia.

Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon to present 8 abstracts on affordability, access and adoption across women's health, biosimilar and general medicines portfolio at ISPOR 2026.

NEW YORK, May 05, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating

Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

The headline numbers for Organon (OGN) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Organon (OGN) came out with quarterly earnings of $0.71 per share, missing the Zacks Consensus Estimate of $0.83 per share. This compares to earnings of $1.02 per share a year ago.

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN) today announced its results for the first quarter ended March 31, 2026. First Quarter 2026 Revenue in $ millions   Q1 2026   Q1 2025   VPY   VPY ex-FX Women's Health   $ 389   $ 463   (16)%   (19)% General Medicines                 Biosimilars     173     141   23%   21% Established Brands     880     887   (1)%   (7)% Other (1)     18     22   (15)%   (21)% Revenue   $ 1,460   $ 1,513   (4)%   (9)%     Totals may not foot due to rounding.